The European Journal of Health Economics

Order information:
Web: http://link.springer.de/orders.htm
Download restrictions: Access to the full text of the articles in this series is restricted.
Editor: J.-M.G.v.d. Schulenburg
For technical questions regarding this series, please contact (Christopher F Baum)
Series handle: repec:spr:eujhec

• 205-207 IQWiG: an opportunity lost?
  by Bengt Jönsson [Downloadable! (restricted)]
• 209-219 Quality of life and cost-effectiveness of acupuncture treatment in patients with osteoarthritis pain
  by Thomas Reinhold & Claudia Witt & Susanne Jena & Benno Brinkhaus & Stefan Willich [Downloadable! (restricted)]
• 221-228 Economic consequences of near-patient test results: the case of tests for the Helicobacter Pylori bacterium in dyspepsia
  by Siri Fauli & Geir Thue [Downloadable! (restricted)]
• 229-236 The cost of treating high blood pressure in general practice in France
  by Yaël Tibi-Levy & Gérard Pouvourville & Jérémie Westerloppe & Marion Bamberger [Downloadable! (restricted)]
• 237-249 An assessment of the discriminative ability of the EQ-5Dindex, SF-6D, and EQ VAS, using sociodemographic factors and clinical conditions
  by Garry Barton & Tracey Sach & Michael Doherty & Anthony Avery & Claire Jenkinson & Kenneth Muir [Downloadable! (restricted)]
• 251-259 Estimating the expected value of partial perfect information: a review of methods
  by Doug Coyle & Jeremy Oakley [Downloadable! (restricted)]
• 261-264 Choice determinants of the mobility in the Dutch health insurance market
  by Ilaria Mosca & Anoushka Schut-Welkzijn [Downloadable! (restricted)]
• 265-274 Predisposing factors for early retirement in patients with Schizophrenia in Germany
  by Reinhard Schnabel & Heiko Friedel & Andreas Erfurth & Matthias Angermayer & Johannes Clouth & Florian Eichmann [Downloadable! (restricted)]
• 275-284 Preferences and utilities for the symptoms of moderate to severe allergic asthma
  by Andrew Lloyd & Scott Doyle & Sarah Dewilde & Florian Turk [Downloadable! (restricted)]
• 285-292 In pursuit of QALY weights for relatives: empirical estimates in relatives caring for older people
  by Thomas Davidson & Barbro Krevers & Lars-Åke Levin [Downloadable! (restricted)]
• 293-304 A theoretical and empirical investigation of nutritional label use
  by Andreas Drichoutis & Panagiotis Lazaridis & Rodolfo Nayga & Maria Kapsokefalou & George Chryssochoidis [Downloadable! (restricted)]
• 305-310 Pricing and reimbursement of pharmaceuticals in Italy
  by Pietro Folino-Gallo & Simona Montilla & Mario Bruzzone & Nello Martini [Downloadable! (restricted)]

• 99-101 The CHESME Health Economic Evaluations Database (CHESME HEED) project
  by Dimitrios Rovithis & Lycurgus Liaropoulos [Downloadable! (restricted)]
• 103-115 Costing maternal health services in South Tanzania
  by Claudia Both & Albrecht Jahn & Steffen Fleßa [Downloadable! (restricted)]
• 117-125 Primary physicians’ response to changes in fees
  by Jostein Grytten & Fredrik Carlsen & Irene Skau [Downloadable! (restricted)]
• 127-136 The search for good compliance: economic aspects of a conveyed combination pharmaco-therapy, exemplified by an osteoporosis therapy
  by Peter Oberender & Jürgen Zerth [Downloadable! (restricted)]
• 137-145 Methodological issues in undertaking independent cost-effectiveness analysis for NICE: the case of therapies for ADHD
  by Susan Griffin & Helen Weatherly & Gerry Richardson & Mike Drummond [Downloadable! (restricted)]
• 147-156 The role of non-need factors in individual GP utilisation analysis and their implications for the pursuance of equity: a cross-country comparison
  by P. McGregor & P. McKee & C. O’Neill [Downloadable! (restricted)]
• 157-163 Eligibility for free GP care, “need” and GP visiting in Ireland
  by A. Nolan & B. Nolan [Downloadable! (restricted)]
• 165-170 Economic evaluation of the treatment of type 2 diabetes with insulin glargine based on the LAPTOP trial
  by Hans Janka & Barbara Högy [Downloadable! (restricted)]
• 171-183 Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective
  by Jonathan Karnon & Thomas Delea & Vicki Barghout [Downloadable! (restricted)]
• 185-191 The impact of generic substitution on price competition in Finland
  by Ville Aalto-Setälä [Downloadable! (restricted)]
• 193-201 Spillover of cause-specific longevity interventions: an independent mortality risk model
  by Liqun Liu [Downloadable! (restricted)]
• 203-203 Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance
  by Barbara Högy & Heinz-Otto Keinecke & Michael Borte [Downloadable! (restricted)]

• 1-6 Alcohol consumption in the EU: health economics and policy issues under a permanent debate
  by Fernando Antoñanzas & Roberto Rodríguez-Ibeas & Emilio Barco & Manuel Ramírez & Mariola Pinillos [Downloadable! (restricted)]
• 7-15 Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects
  by Adam Lloyd & Nishma Patel & David Scott & Claus Runge & Christa Claes & Markus Rose [Downloadable! (restricted)]
• 17-22 Estimation and comparison of ostomy appliance costs with tariffs in Belgium
  by Veerle Vanleene & Luc Maré & Ingrid Moldenaers & Hans Debruyne & Steven Simoens & Dirk Steen & Dirk Ramaekers [Downloadable! (restricted)]
• 23-32 Influence of bacterial resistances on the efficiency of antibiotic treatments for community-acquired pneumonia
  by Ramon Sabes-Figuera & José Segú & Jaume Puig-Junoy & Antoni Torres [Downloadable! (restricted)]
• 33-39 Vaccination versus “wait and treat”: how to subsidize them?
  by Louis Eeckhoudt & Maurice Marchand & Pierre Pestieau & Gwenaël Piaser [Downloadable! (restricted)]
• 41-50 The differences in characteristics between health-care users and non-users: implication for introducing community-based health insurance in Burkina Faso
  by Hengjin Dong & Adjima Gbangou & Manuela Allegri & Subhash Pokhrel & Rainer Sauerborn [Downloadable! (restricted)]
• 51-61 Work environment satisfaction and employee health: panel evidence from Denmark, France and Spain, 1994–2001
  by Nabanita Datta Gupta & Nicolai Kristensen [Downloadable! (restricted)]
• 63-67 Does greater exposure to own-health data make a difference on the visual analog scale?
  by Amir Shmueli & David Messika & Havi Murad & Laurence Freedman [Downloadable! (restricted)]
• 69-78 Willingness to pay for a reduction in mortality risk after a myocardial infarction: an application of the contingent valuation method to the case of eplerenone
  by Jose-Luis Pinto-Prades & Veronica Farreras & Jaime de Bobadilla [Downloadable! (restricted)]
• 79-86 Factors influencing hospital costs of lung cancer patients in Northern Ireland
  by Ian Fleming & Pauline Monaghan & Anna Gavin & Ciaran O’Neill [Downloadable! (restricted)]
• 87-97 Pharmaceutical pricing and reimbursement reforms in Greece
  by John Yfantopoulos [Downloadable! (restricted)]

• 33-34 Patient access to rheumatoid arthritis treatments
  by Bengt Jönsson & Gisela Kobelt & Josef Smolen [Downloadable! (restricted)]
• 35-38 Patient access to rheumatoid arthritis treatments
  by Bengt Jönsson [Downloadable! (restricted)]
• 39-47 The burden of rheumatoid arthritis and access to treatment: a medical overview
  by J. Smolen & D. Aletaha [Downloadable! (restricted)]
• 49-60 The burden of rheumatoid arthritis and access to treatment: health burden and costs
  by J. Lundkvist & F. Kastäng & G. Kobelt [Downloadable! (restricted)]
• 61-86 The burden of rheumatoid arthritis and access to treatment: uptake of new therapies
  by B. Jönsson & G. Kobelt & J. Smolen [Downloadable! (restricted)]
• 87-93 The burden of rheumatoid arthritis and access to treatment: determinants of access
  by J. Lundqvist & F. Kastäng & G. Kobelt & B. Jönsson [Downloadable! (restricted)]
• 95-106 The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments
  by G. Kobelt & B. Jönsson [Downloadable! (restricted)]

• 301-304 Tobacco policies in the European Union: a need for state and continental harmonisation?
  by Fernando Antoñanzas & Roberto Rodríguez [Downloadable! (restricted)]
• 305-312 Foreign direct investment in the health care sector and most-favoured locations in developing countries
  by J. Outreville [Downloadable! (restricted)]
• 313-323 Cost-effectiveness of extended prophylaxis with fondaparinux compared with low molecular weight heparin against venous thromboembolism in patients undergoing hip fracture surgery
  by Jonas Lundkvist & David Bergqvist & Bengt Jönsson [Downloadable! (restricted)]
• 325-332 The impact of home hospitalization on healthcare costs of exacerbations in COPD patients
  by Jaume Puig-Junoy & Alejandro Casas & Jaume Font-Planells & Joan Escarrabill & Carme Hernández & Jordi Alonso & Eva Farrero & Gemma Vilagut & Josep Roca [Downloadable! (restricted)]
• 333-337 Pricing matrix model: dealing with uncertainty
  by Mark Nuijten [Downloadable! (restricted)]
• 339-346 The incidence and cost of cardiac surgery adverse events in Australian (Victorian) hospitals 2003–2004
  by Jonathon Ehsani & Stephen Duckett & Terri Jackson [Downloadable! (restricted)]
• 347-357 Assessment of the pharmaceutical market in Poland after accession to the European Union
  by Patricia Willert [Downloadable! (restricted)]
• 359-359 Costs and quality of life in multiple sclerosis in The Netherlands
  by Gisela Kobelt & Jenny Berg & Peter Lindgren & Bert Anten & Mattias Ekman & Peter Jongen & Chris Polman & Bernard Uitdehaag [Downloadable! (restricted)]

• 179-179 Editor’s note
  by J.-Matthias Graf von der Schulenburg & Wolfgang Greiner [Downloadable! (restricted)]
• 181-193 Innovation in hospitals: a survey of the literature
  by Faridah Djellal & Faïz Gallouj [Downloadable! (restricted)]
• 195-212 Risk adjustment policy options for casemix funding: international lessons in financing reform
  by Kathryn Antioch & Randall Ellis & Steve Gillett & Daniel Borovnicar & Ric Marshall [Downloadable! (restricted)]
• 213-223 Incorporating efficiency in hospital-capacity planning in Germany
  by Ludwig Kuntz & Stefan Scholtes & Antonio Vera [Downloadable! (restricted)]
• 225-236 Variations in activity and practice patterns: a French study for GPs
  by Sophie Béjean & Christine Peyron & Renaud Urbinelli [Downloadable! (restricted)]
• 237-243 Income-related health inequality in Belgium: a longitudinal perspective
  by Ann Lecluyse [Downloadable! (restricted)]
• 245-251 Economic impact of shifting the locus of care for neuropathic pain from specialists to general practitioners
  by Ariel Berger & Piotr Kramarz & Gry Kopperud & John Edelsberg & Gerry Oster [Downloadable! (restricted)]
• 253-266 Patient access to pharmaceuticals: an international comparison
  by Joshua Cohen & Laura Faden & Susan Predaris & Brian Young [Downloadable! (restricted)]
• 267-277 Supplier-induced demand: re-examining identification and misspecification in cross-sectional analysis
  by Stuart Peacock & Jeffrey Richardson [Downloadable! (restricted)]
• 279-285 Is there an association between economic performance and public satisfaction in health care?
  by Eddy Adang & George Borm [Downloadable! (restricted)]
• 287-295 Why do patients bypass the nearest hospital? An empirical analysis for orthopaedic care and neurosurgery in the Netherlands
  by Marco Varkevisser & Stéphanie Geest [Downloadable! (restricted)]
• 297-300 Economic aspects of the new Spanish laws on pharmaceutical preparations
  by Fernando Antoñanzas & Juan Oliva & Mariola Pinillos & Carmelo Juàrez [Downloadable! (restricted)]

• 83-88 The time for cost-effectiveness in the new European Union member states: the development and role of health economics and technology assessment in the mirror of the Hungarian experience
  by László Gulácsi [Downloadable! (restricted)]
• 89-95 Pharmacoeconomic studies in Italy: a critical review of the literature
  by D. Cornago & L. Li Bassi & P. Compadri & L. Garattini [Downloadable! (restricted)]
• 97-103 The burden of type 2 diabetes in Serbia and the cost-effectiveness of its management
  by Vesna Bjegovic & Zorica Terzic & Jelena Marinkovic & Nebojsa Lalic & Sandra Sipetic & Ulrich Laaser [Downloadable! (restricted)]
• 105-110 Patients’ willingness to pay for electronic communication with their general practitioner
  by Trine Bergmo & Silje Wangberg [Downloadable! (restricted)]
• 111-121 Systematic review of economic evaluations and cost analyses of guideline implementation strategies
  by Luke Vale & Ruth Thomas & Graeme MacLennan & Jeremy Grimshaw [Downloadable! (restricted)]
• 123-135 Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain
  by Maureen Rutten-van Mölken & Jan Oostenbrink & Marc Miravitlles & Brigitta Monz [Downloadable! (restricted)]
• 137-144 The cost-utility of magnetic resonance imaging for breast cancer in BRCA1 mutation carriers aged 30–49
  by Richard Norman & D. Evans & Douglas Easton & Kenneth Young [Downloadable! (restricted)]
• 145-151 Comparative cost-minimisation of oral and intravenous chemotherapy for first-line treatment of non-small cell lung cancer in the UK NHS system
  by K. Le Lay & E. Myon & S. Hill & L. Riou-Franca & D. Scott & M. Sidhu & D. Dunlop & R. Launois [Downloadable! (restricted)]
• 153-160 An economic analysis of human papillomavirus triage for the management of women with atypical and abnormal Pap smear results in Germany
  by Sara Sheriff & K. Petry & Hans Ikenberg & Geoffrey Crouse & Peter Mazonson & Christopher Santas [Downloadable! (restricted)]
• 161-168 Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis
  by Andrew Palmer & William Valentine & Joshua Ray & Stephane Roze & Noemi Muszbek [Downloadable! (restricted)]
• 169-170 Comment on: Should we really worry about “launch delays” of new drugs in OECD countries? by L. Garatinni and S. Ghislandi
  by Joshua Cohen [Downloadable! (restricted)]
• 171-171 Should we really worry about “launch delays” of new drugs in OECD countries? Reply to J Cohen
  by Livio Garattini [Downloadable! (restricted)]
• 173-177 Discussion point: should governments buy drug patents?
  by Juan Llano [Downloadable! (restricted)]

• 1-3 Should we really worry about “launch delays” of new drugs in OECD countries?
  by Livio Garattini & Simone Ghislandi [Downloadable! (restricted)]
• 3-3 Technology assessment in the German context
  by Michael Drummond [Downloadable! (restricted)]
• 5-15 Cost of breast cancer in Sweden in 2002
  by Mathias Lidgren & Nils Wilking & Bengt Jönsson [Downloadable! (restricted)]
• 17-24 Better primary physician services lead to fewer hospital admissions
  by Fredrik Carlsen & Jostein Grytten & Julie Kjelvik & Irene Skau [Downloadable! (restricted)]
• 25-30 Utility loss and indirect costs following cardiovascular events in hypertensive patients: the ASCOT health economic substudy
  by Peter Lindgren & Thomas Kahan & Neil Poulter & Martin Buxton & Patrick Svarvar & Björn Dahlöf & Bengt Jönsson [Downloadable! (restricted)]
• 31-39 Risk-adjusted capitation payments: how well do principal inpatient diagnosis-based models work in the German situation? Results from a large data set
  by Corinne Behrend & Florian Buchner & Michael Happich & Rolf Holle & Peter Reitmeir & Jürgen Wasem [Downloadable! (restricted)]
• 41-50 Long-term absenteeism due to sickness in Sweden. How long does it take and what happens after?
  by Daniela Andrén [Downloadable! (restricted)]
• 51-57 Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany
  by B. Brüggenjürgen & P. Lindgren & B. Ehlken & H.-J. Rupprecht & S. Willich [Downloadable! (restricted)]
• 59-65 A multilevel analysis on the determinants of regional health care expenditure: a note
  by Guillem López-Casasnovas & Marc Saez [Downloadable! (restricted)]
• 67-76 Resource use and costs associated with patients treated for depression in primary care
  by P. Sobocki & M. Ekman & H. Ågren & I. Krakau & B. Runeson & B. Mårtensson & B. Jönsson [Downloadable! (restricted)]
• 77-82 A public–private analysis of the new Dutch health insurance system
  by Hans Maarse & Yvette Bartholomée [Downloadable! (restricted)]
• 5-31 Methods for determining cost-benefit ratios for pharmaceuticals in Germany
  by J.- Graf v. d. Schulenburg & Christoph Vauth & Thomas Mittendorf & Wolfgang Greiner [Downloadable! (restricted)]
• 1-2 Economic evaluation for pharmaceuticals in Germany
  by Bengt Jönsson [Downloadable! (restricted)]

• 223-224 Time for a common standard for cost-effectiveness in Europe?
  by Bengt Jönsson [Downloadable! (restricted)]
• 225-230 Optional deductibles in social health insurance systems
  by Claudia Pütz & Christian Hagist [Downloadable! (restricted)]
• 231-237 A decomposition of income-related health inequality applied to EQ-5D
  by Jens Gundgaard & Jørgen Lauridsen [Downloadable! (restricted)]
• 238-246 Cost effectiveness of preventive home visits to the elderly
  by Christian Kronborg & Mikkel Vass & Jørgen Lauridsen & Kirsten Avlund [Downloadable! (restricted)]
• 247-254 Cost-benefit analysis of a plant sterol containing low-fat margarine for cholesterol reduction
  by A. Gerber & T. Evers & H. Haverkamp & K. Lauterbach [Downloadable! (restricted)]
• 255-264 Cost-effectiveness of the Danish smoking cessation interventions
  by Kim Olsen & Lone Bilde & Henrik Juhl & Niels Kjaer & Holger Mosbech & Torben Evald & Mette Rasmussen & Helle Hiladakis [Downloadable! (restricted)]
• 265-269 The demand for private health care under national health insurance
  by Y. Machnes [Downloadable! (restricted)]
• 270-275 Economic cost associated with type II diabetes in Spanish patients
  by Miguel Ballesta & Florentino Carral & Gabriel Olveira & José Girón & Manuel Aguilar [Downloadable! (restricted)]
• 276-284 Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany
  by Alan Brennan & Roberta Ara & Raimund Sterz & Bernd Matiba & Rito Bergemann [Downloadable! (restricted)]
• 285-289 Tests of stationarity and cointegration of health care expenditure and gross domestic product
  by Halil Kiymaz & Yasemin Akbulut & Ahmet Demir [Downloadable! (restricted)]
• 290-296 Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany
  by W. Greiner & K. Lehmann & S. Earnshaw & C. Bug & R. Sabatowski [Downloadable! (restricted)]

• 155-157 Risk-sharing agreements for innovative drugs
  by Gérard Pouvourville [Downloadable! (restricted)]
• 158-164 Nonmedical economic consequences attributable to visual impairment
  by Antoine Lafuma & Antoine Brezin & Francis Fagnani & Viviane Mimaud & Mounir Mesbah & Gilles Berdeaux [Downloadable! (restricted)]
• 165-172 A decision model to compare health care costs of olanzapine and risperidone treatment for schizophrenia in Germany
  by Stephen Beard & Fiona Maciver & Johannes Clouth & Eckart Rüther [Downloadable! (restricted)]
• 173-178 Test-retest reliability of willingness to pay
  by Alan Shiell & Penelope Hawe [Downloadable! (restricted)]
• 179-184 The costs of schizophrenia in Spain
  by Juan Oliva-Moreno & Julio López-Bastida & Rubén Osuna-Guerrero & Angel Montejo-González & Beatriz Duque-González [Downloadable! (restricted)]
• 185-191 Health care in the CIS countries
  by Anatoly Pilyavsky & Matthias Staat [Downloadable! (restricted)]
• 192-194 Problems and costs associated with alcohol and drug abuse in emergency medicine
  by F.-X. Huber & T. Hackert & P. Meeder [Downloadable! (restricted)]
• 195-203 Determinants of household health expenditure on western institutional health care
  by Tin Su & Subhash Pokhrel & Adjima Gbangou & Steffen Flessa [Downloadable! (restricted)]
• 204-211 Price regulation and generic competition in the pharmaceutical market
  by Dag Dalen & Steinar Strøm & Tonje Haabeth [Downloadable! (restricted)]
• 212-217 Alcohol-related mortality, drinking behavior, and business cycles
  by Edvard Johansson & Petri Böckerman & Ritva Prättälä & Antti Uutela [Downloadable! (restricted)]
• 218-220 Decision models in the evaluation of psychotropic drugs
  by Corrado Barbui & Camilla Lintas [Downloadable! (restricted)]

• 55-64 Costs and quality of life in multiple sclerosis in The Netherlands
  by Gisela Kobelt & J. Berg & P. Lindgren [Downloadable! (restricted)]
• 89-90 Pharmaceutical policy in Italy
  by Livio Garattini & Dante Cornago [Downloadable! (restricted)]
• 91-98 The reasons of general practitioners for promoting colorectal cancer mass screening in France
  by Célia Berchi & Jean-Marc Dupuis & Guy Launoy [Downloadable! (restricted)]
• 99-106 Choices and utilization in dental care
  by Lien Nguyen & Unto Häkkinen [Downloadable! (restricted)]
• 107-113 Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer
  by Samuel Limat & Claire-Hélène Bracco-Nolin & Christine Legat-Fagnoni & Loic Chaigneau & Ulrich Stein & Bernard Huchet & Xavier Pivot & Marie-Christine Woronoff-Lemsi [Downloadable! (restricted)]
• 114-116 Health care and patients’ migration across Spanish regions
  by David Cantarero [Downloadable! (restricted)]
• 117-122 The future of imaging techniques for cancer patients in The Netherlands
  by Theo Postma & Janneke Alers & Sijmon Terpstra & Arjan Zuurbier [Downloadable! (restricted)]
• 123-128 Factors influencing the costs of emergency medical admissions to an Irish teaching hospital
  by Edward Moloney & Kathleen Bennett & Bernard Silke [Downloadable! (restricted)]
• 129-136 Outcomes research collaborations between third-party payers, academia, and pharmaceutical manufacturers
  by Hans-Georg Eichler & Sheldon Kong & Jean-Pierre Grégoire [Downloadable! (restricted)]
• 137-144 Cost-effectiveness of memantine in community-based Alzheimer’s disease patients: an adaptation in Spain
  by Fernando Antonanzas & Benoit Rive & Josep Badenas & Susana Gomez-Lus & Chantal Guilhaume [Downloadable! (restricted)]
• 145-146 Costs of chemotherapy in the treatment of colorectal cancer
  by F. Jansman & M. Postma [Downloadable! (restricted)]
• 147-151 A taxonomy of health utility assessment methods and the role for uncertainty analysis
  by Agota Szende & Caroline Schaefer [Downloadable! (restricted)]

• 5-6 The desirability and feasibility of economic studies of drugs post-launch
  by Michael Drummond & Anne Mason & Adrian Towse [Downloadable! (restricted)]
• 7-18 The relationship between health care expenditure and health outcomes
  by John Nixon & Philippe Ulmann [Downloadable! (restricted)]
• 19-29 Pharmacoeconomic modelling in schizophrenia
  by Karina Hansen & Christophe Lançon & Mondher Toumi [Downloadable! (restricted)]
• 30-36 Comparing costs and effectiveness of different starting points for highly active antiretroviral therapy in HIV-positive patients
  by Monica Merito & Patrizio Pezzotti [Downloadable! (restricted)]
• 37-45 Fixed budgets as a cost containment measure for pharmaceuticals
  by David Granlund & Niklas Rudholm & Magnus Wikström [Downloadable! (restricted)]
• 46-54 The Danish effect on Swedish alcohol costs
  by Johan Jarl & Ulf-G. Gerdtham & Carl Lyttkens & Thor Lithman & Juan Merlo [Downloadable! (restricted)]
• 55-65 Prospective casemix-based funding, analysis and financial impact of cost outliers in all-patient refined diagnosis related groups in three Belgian general hospitals
  by Magali Pirson & Dimitri Martins & Terri Jackson & Michèle Dramaix & Pol Leclercq [Downloadable! (restricted)]
• 66-71 Case-control analysis of the financial cost of medication errors in hospitalized patients
  by Jaime Pinilla & Carles Murillo & Genís Carrasco & Carlos Humet [Downloadable! (restricted)]
• 72-78 Cost-utility analysis comparing meropenem with imipenem plus cilastatin in the treatment of severe infections in intensive care
  by Steven Edwards & Helen Campbell & Jonathan Plumb [Downloadable! (restricted)]
• 79-83 Off-patent drugs in Italy
  by Livio Garattini & Simone Ghislandi [Downloadable! (restricted)]

Did you know? Data contributors to RePEc receive monthly emails with details about downloads and abstract views of their works.

This page was last updated on 2008-9-4.